My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Summit Therapeutics Inc. - Common Stock (NQ:SMMT)

18.81 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Dec 4, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Summit Therapeutics Inc. - Common Stock

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

August 19, 2022

We're starting the final day of trading this week with a look at the biggest pre-market stock movers for Friday and what's moving them!

Via InvestorPlace

August 19, 2022

Gainers

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

August 18, 2022

Via Benzinga

Summit Therapeutics Mulls Additional Trial For Its Once Failed Infection Candidate ↗

July 14, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

May 11, 2022

On Wednesday, 807 companies reached new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

April 26, 2022

During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.

Via Benzinga

OncoCyte And 2 Other Stocks Under $1 Insiders Are Aggressively Buying ↗

August 18, 2022

The Dow Jones dropped by around 170 points on Wednesday following the release of Fed minutes. Investors, meanwhile, focused on some notable insider trades.

Via Benzinga

Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy ↗

July 27, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Daily Biotech Pulse: F-Star Therapeutics Buyout, Orphan Drug Tag For VBI's Brain Cancer Vaccine, Xenon's Epilepsy Candidate Shows Promise ↗

June 23, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

June 22, 2022

Gainers ABVC BioPharma (NASDAQ:ABVC) shares increased by 12.3% to $1.03 during Wednesday's after-market session. The company's market cap stands at $33.2 million.

Via Benzinga

Pfizer’s CDI Trial Miss Puts Acurx Pharmaceuticals Ibezapolstat In Front-Line Position, Here’s Why Big Pharma May Come Calling ($ACXP)

June 09, 2022

Via AB Newswire

Acurx Pharmaceuticals Is Under The Radar, That’s Excellent News For Investors Wanting Exposure To Billion Dollar CDI Treatment Market ($ACXP)

June 06, 2022

Via AB Newswire

Stocks That Hit 52-Week Lows On Wednesday ↗

May 25, 2022

On Wednesday, 215 companies set new 52-week lows.

Via Benzinga

77 Biggest Movers From Yesterday ↗

June 01, 2022

Gainers TherapeuticsMD, Inc. (NASDAQ: TXMD) shares climbed 364% to close at $9.93 on Tuesday after the company announced it has entered into a definitive merger agreement to be acquired by an affiliate...

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

April 29, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

May 04, 2022

During Wednesday's trading, 435 companies set new 52-week lows.

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

April 25, 2022

Via Benzinga

Acurx Pharmaceuticals Stands As Front-Line CDI Treatment Contender After Pfizer Misses Primary Endpoint In CDI Drug Trial (NASDAQ: ACXP)

March 28, 2022

Via AB Newswire

Analyzing Summit Therapeutics Inc's Short Interest ↗

March 21, 2022

Summit Therapeutics Inc's (NASDAQ:SMMT) short percent of float has risen 50.18% since its last report. The company recently reported that it has 1.06 million shares sold short,...

Via Benzinga

Acurx Pharmaceuticals Ibezapolstat Targets Front-Line Opportunity After Pfizer Fails To Reach CDI Trial Primary Endpoint (NASDAQ: ACXP)

March 07, 2022

Via AB Newswire

80 Biggest Movers From Yesterday ↗

March 02, 2022

Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI) jumped 78.5% to close at $0.6066 on Tuesday after jumping 36% on Monday. CTI BioPharma Corp. (NASDAQ: CTIC) surged 63...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

March 01, 2022

Gainers Organogenesis Holdings (NASDAQ:ORGO

Via Benzinga

88 Biggest Movers From Yesterday ↗

February 25, 2022

Gainers Cyren Ltd. (NASDAQ: CYRN) shares surged 118.9% to settle at $4.75 on Thursday. Cyren recently announced a $12 million private placement. Indonesia Energy Corporation...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

January 26, 2022

Gainers Vaccinex (NASDAQ:VCNX) shares moved upwards by 30.4% to $1.33 during Wednesday's pre-market session. The market value of their outstanding shares is at $40.9...

Via Benzinga

Acurx Pharmaceuticals’ Ibezapolstat Takes Center Stage After Summit Therapeutics Misses Phase 3 C.Diff Trial Endpoints (NASDAQ: ACXP)

January 03, 2022

Via AB Newswire

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Summit Therapeutics Inc. with Losses of $100,000 to Contact the Firm

December 28, 2021

From The Schall Law Firm

Via Business Wire

Mid-Afternoon Market Update: Dow Tumbles 500 Points; Bluerock Residential Growth Shares Spike Higher ↗

December 20, 2021

Toward the end of trading Monday, the Dow traded down 1.42% to 34,862.49 while the NASDAQ fell 1.38% to 14,960.51. The S&P also fell, dropping 1.34% to 4,558.87. The U.S. has...

Via Benzinga

65 Biggest Movers From Yesterday ↗

December 21, 2021

Gainers Society Pass Incorporated (NASDAQ: SOPA) shares climbed 240.2% to close at $11.26 on Monday after the company reported addition to the Russell 2000 Index. Bluerock...

Via Benzinga

Summit Therapeutics' Infection Candidate Flunks In Head-To-Head Trial ↗

December 20, 2021

Summit Therapeutics Inc (NASDAQ: SMMT) shares are trading lower after disappointing results from the Phase 3 Ri-CoDIFy study of ridinilazole for C. difficile...

Via Benzinga

Selloff Deepens as Covid-19 Casts Shadow Over Holidays ↗

December 20, 2021

This morning's selloff has deepened by midday, as investors assess how the rapidly spreading Covid-19 omicron variant could impact the holiday season.

Via Talk Markets

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.